N.J. drugmaker Merck reports new antiviral COVID drug quickly reduces virus
New Jersey-based Merck said Saturday that the experimental antiviral drug molnupiravir it has been developing with Ridgeback Bio showed a quick reduction of the infectious virus in a study among participants with early COVID-19.
“We continue to make progress in our Phase 2/3 clinical programs evaluating molnupiravir in both outpatient and hospital settings,” said Roy Baynes, head of global clinical development and chief medical officer at Merck Research Laboratories.
Ridgeback Biotherapeutics is a biotechnology company focused on emerging infectious diseases. It currently markets Ebanga for th…
More from my site
Next Up: Major Contact-Tracing Program to Keep the Virus in Check?
Bill to legalize recreational marijuana in N.J. set to be unveiled
Grewal limits Hydroxychloroquine and Chloroquine Prescriptions
Christie Shouts Down Protesters In Shrewsbury
A Role for Retired Officers as Pandemic Depletes Police Departments
State Dept Report: Virus pandemic has led to rise in human trafficking
Joint Chiefs chairman: U.S. probing whether coronavirus escaped a Chinese lab
Murphy’s Reliance on a Fallible Medical Profession and COVID-19: School Graduation Edition –DeSeno
The world deserves a better, totally transparent and accountable, WHO
N.J. coronavirus deaths surge to 3,840 with 78,467 total cases now confirmed. Officials report 323 new deaths, 3,250 new positive tests.